Log in to save to my catalogue

Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐lab...

Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐lab...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d703d6568c29415c8e2d93ccf47af5d0

Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19

About this item

Full title

Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19

Publisher

United States: John Wiley & Sons, Inc

Journal title

Clinical and translational science, 2021-05, Vol.14 (3), p.1133-1146

Language

English

Formats

Publication information

Publisher

United States: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

We applied a set of in silico and in vitro assays, compliant with the Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm, to assess the risk of chloroquine (CLQ) or hydroxychloroquine (OH‐CLQ)‐mediated QT prolongation and Torsades de Pointes (TdP), alone and combined with erythromycin (ERT) and azithromycin (AZI), drugs repurposed during th...

Alternative Titles

Full title

Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_d703d6568c29415c8e2d93ccf47af5d0

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d703d6568c29415c8e2d93ccf47af5d0

Other Identifiers

ISSN

1752-8054

E-ISSN

1752-8062

DOI

10.1111/cts.13011

How to access this item